The Mortgage Bankers Association (MBA) released its weekly report on mortgage applications Wednesday morning, noting a decrease of 0.5% in the group’s seasonally adjusted composite index for the week ending June 29. Mortgage loan rate movements were mixed last week.
This week, I told my Maximum Income readers that I’m optimistic after seeing the earnings reports so far this quarter. There is room for upside in the current stock market, although there are also risks.
I laid out my reasoning for this in detail to my subscribers, but what’s important to know is that all this indicates to me that our focus needs to remain in safety.
Today Money Morning is publishing a list of the five top penny stocks to watch in November. These stocks have all already seen gains over 250% year to date (YTD) and could easily continue their runs this month.
What’s more, the No. 1 penny stock to watch in November has posted YTD gains of nearly 430%…
While we’re excited about the potential gains of these five....More>>>
Every week, I compile a table of all U.S.-listed stocks with dividend yields of 10% or higher. Some of the names come and go, while others reappear time and again. I’ve become familiar with many of them, and can safely say that the list is dominated by tiny companies with market caps between $50 million and $300 million.
While it’s open to debate whether President Donald Trump made America great, the 2016 election did produce one undeniable result: it laid the foundation for cannabis-related businesses, thereby dramatically improving profitability potential for marijuana penny stocks.
During the general election, a record number of states voted for marijuana legalization to varying degrees. Of those....More>>>
Shares of IMPINJ (NASDAQ:PI) are soaring today, reaching a peak gain of 33.5% near 10:40 a.m., EDT. The maker of tools and equipment for tracking real-world goods in computer systems with RAIN RFID technologies reported first-quarter results roughly in line with analyst targets, alongside a modest view of the upcoming second quarter.
Pennymac Mortgage Investment (NYSE:PMT) – Equities researchers at Wedbush lifted their Q1 2019 earnings per share estimates for shares of Pennymac Mortgage Investment in a research note issued to investors on Thursday, May 10th. Wedbush analyst J. Weaver now anticipates that the real estate investment trust will post earnings per share of $0.36 for the quarter, up from their previous estimate....More>>>
The fear over 10-year U.S. Treasury yields breaking through 3 percent has been a long time coming, according to Societe Generale SA.
“Interest rates are already doing damage, people just haven’t noticed,” Andrew Lapthorne, the firm’s global head of quantitative strategy, said in an interview Tuesday. “Leverage in the U.S. is grotesque for this stage of the....More>>>
SOFIA, Bulgaria The European Union has called on U.S. President Donald Trump's administration to stop threating it with tariffs on steel and aluminum, saying Thursday it is prepared to discuss trade but not at gun-point.
In March, Trump slapped tariffs of 25% on steel imports and 10% on impo
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...
Editor's note: Seeking Alpha is proud to welcome Michael McGrath as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more 禄
If you're not familiar with how Social Security works, you might assume that there's a single age at which eligible recipients have to file for benefits. Not so. You actually get an eight-year window to claim benefits that begins at age 62 and carries through until age 70. (Technically, you're no
The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president's blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.